Value of PAX8 and WT1 immunostaining in confirming the ovarian origin of metastatic carcinoma in serous effusion specimens

American Journal of Clinical Pathology

Volumn 137, Issue 2, 2012, Pages 304-309

  Zhao, Lichao ^a   Guo, Ming ^a   Sneige, Nour ^a   Gong, Yun ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Effusion; Metastatic; Ovarian; PAX8; WT1

Indexed keywords

BIOLOGICAL MARKER; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR PAX8; TRANSCRIPTION FACTOR WT1; UNCLASSIFIED DRUG;

ARTICLE; CLEAR CELL CARCINOMA; CYTODIAGNOSIS; EFFUSION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; METASTASIS; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMEAR;

ASCITIC FLUID; CYSTADENOCARCINOMA, SEROUS; FEMALE; HUMANS; OVARIAN NEOPLASMS; PAIRED BOX TRANSCRIPTION FACTORS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; WT1 PROTEINS;

EID: 84863393791     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPU0FION3RKKFO     Document Type: Article

References (33)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-249.
2. Wikborn C, Pettersson F, Moberg PJ. Delay in diagnosis of epithelial ovarian cancer. Int J Gynaecol Obstet. 1996;52:263-267. (Pubitemid 26073242)
3. Goff BA, Mandel LS, Melancon CH, et al. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA. 2004;291:2705-2712. (Pubitemid 38725419)
4. Auersperg N, Wong AS, Choi KC, et al. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev. 2001;22:255-288. (Pubitemid 32458162)
5. Koonings PP, Campbell K, Mishell DR Jr, et al. Relative frequency of primary ovarian neoplasms: a 10-year review. Obstet Gynecol. 1989;74:921-926. (Pubitemid 20003288)
6. Kurman RJ, Shih IeM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol. 2010;34:433-443.
7. Pereira TC, Saad RS, Liu Y, et al. The diagnosis of malignancy in effusion cytology: a pattern recognition approach. Adv Anat Pathol. 2006;13:174-184. (Pubitemid 44341653)
8. Ko EC, Jhala NC, Shultz JJ, et al. Use of a panel of markers in the differential diagnosis of adenocarcinoma and reactive mesothelial cells in fluid cytology. Am J Clin Pathol. 2001;116:709-715. (Pubitemid 34453212)
9. Ordonez NG. Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas. Am J Surg Pathol. 1998;22:1203-1214. (Pubitemid 28462768)
10. Ordonez NG. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am J Surg Pathol. 2003;27:1031-1051. (Pubitemid 36909525)
11. Cangi MG, Pecciarini L, Doglioni C. The role of immunohistochemistry in the differential diagnosis of serous effusions. Adv Clin Path. 2000;4:183-185.
12. Wick MR, Moran CA, Mills SE, et al. Immunohistochemical differential diagnosis of pleural effusions, with emphasis on malignant mesothelioma. Curr Opin Pulm Med. 2001;7:187-192. (Pubitemid 32675383)
13. Al-Hussaini M, Stockman A, Foster H, et al. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology. 2004;44:109-115. (Pubitemid 38296970)
14. Hwang H, Quenneville L, Yaziji H, et al. Wilms tumor gene product: sensitive and contextually specific marker of serous carcinomas of ovarian surface epithelial origin. Appl Immunohistochem Mol Morphol. 2004;12:122-126. (Pubitemid 38788760)
15. Hylander B, Repasky E, Shrikant P, et al. Expression of Wilms tumor gene (WT1) in epithelial ovarian cancer. Gynecol Oncol. 2006;101:12-17.
16. Goldstein NS, Bassi D, Uzieblo A. WT1 is an integral component of an antibody panel to distinguish pancreaticobiliary and some ovarian epithelial neoplasms. Am J Clin Pathol. 2001;116:246-252. (Pubitemid 33044330)
17. Lee BH, Hecht JL, Pinkus JL, et al. WT1, estrogen receptor, and progesterone receptor as markers for breast or ovarian primary sites in metastatic adenocarcinoma to body fluids. Am J Clin Pathol. 2002;117:745-750. (Pubitemid 34457009)
18. McKnight R, Cohen C, Siddiqui MT. Utility of paired box gene 8 (PAX8) expression in fluid and fine-needle aspiration cytology: an immunohistochemical study of metastatic ovarian serous carcinoma. Cancer Cytopathol. 2010;118:298-302.
19. Nonaka D, Chiriboga L, Soslow RA. Expression of PAX8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas. Am J Surg Pathol. 2008;32:1566-1571.
20. Bowen NJ, Logani S, Dickerson EB, et al. Emerging roles for PAX8 in ovarian cancer and endosalpingeal development. Gynecol Oncol. 2007;104:331-337. (Pubitemid 46135661)
21. Siehl JM, Thiel E, Heufelder K, et al. Possible regulation of Wilms' tumour gene 1 (WT1) expression by the paired box genes PAX2 and PAX8 and by the haematopoietic transcription factor GATA-1 in human acute myeloid leukaemias. Br J Haematol. 2003;123:235-242. (Pubitemid 37305057)
22. Tong GX, Devaraj K, Hamele-Bena D, et al. PAX8: a marker for carcinoma of müllerian origin in serous effusions. Diagn Cytopathol. 2011;39:567-574.
23. Wiseman W, Michael CW, Roh MH. Diagnostic utility of PAX8 and PAX2 immunohistochemistry in the identification of metastatic müllerian carcinoma in effusions. Diagn Cytopathol. 2011;39:651-656.
24. Davidson B. Malignant effusions: from diagnosis to biology. Diagn Cytopathol. 2004;31:246-254. (Pubitemid 39314820)
25. Monte SA, Ehya H, Lang WR. Positive effusion cytology as the initial presentation of malignancy. Acta Cytol. 1987;31:448-452. (Pubitemid 17126855)
26. Antic T, Gong Y, Sneige N. Tumor type and single-cell/mesothelial-like cell pattern of breast carcinoma metastases in pleural and peritoneal effusions [published online ahead of print November 22, 2010]. Diagn Cytopathol. doi:10.1002/dc.21563.
27. Shimizu M, Toki T, Takagi Y, et al. Immunohistochemical detection of the Wilms' tumor gene (WT1) in epithelial ovarian tumors. Int J Gynecol Pathol. 2000;19:158-163. (Pubitemid 30212153)
28. Gong Y, Symmans WF, Krishnamurthy S, et al. Optimal fixation conditions for immunocytochemical analysis of estrogen receptor in cytologic specimens of breast carcinoma. Cancer. 2004;102:34-40. (Pubitemid 38209571)
29. Gong Y, Han EY, Guo M, et al. Stability of estrogen receptor status in breast carcinoma: a comparison between primary and metastatic tumors with regard to disease course and intervening systemic therapy. Cancer. 2011;117:705-713.
30. Ordonez NG. Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma. Am J Surg Pathol. 2000;24:598-606. (Pubitemid 30180755)
31. Tacha D, Zhou D, Cheng L. Expression of PAX8 in normal and neoplastic tissues: a comprehensive immunohistochemical study. Appl Immunohistochem Mol Morphol. 2011;19:293-299.
32. Goldstein NS, Uzieblo A. WT1 immunoreactivity in uterine papillary serous carcinomas is different from ovarian serous carcinomas. Am J Clin Pathol. 2002;117:541-545. (Pubitemid 34823682)
33. Laury AR, Hornick JL, Perets R, et al. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma. Am J Surg Pathol. 2010;34:627-635.